Skip to main content

ATRT: Advancing Targeted, Refined Treatments Grant

Project Title

Targeting mesenchymal cells in atypical teratoid rhabdoid tumors

Layman’s summary

Atypical teratoid rhabdoid tumor (ATRT) is a highly aggressive brain cancer in children under 3, with current treatments causing severe side effects and developmental problems. Many ATRT cells have a “mesenchymal” shape that drives rapid growth and invasion, and this project aims to target this feature by disrupting vimentin, a key protein in mesenchymal cells, using a novel drug called FiVe1. The research seeks to develop more precise, less toxic therapies by focusing on the unique biology of ATRT tumors, ultimately improving outcomes for affected children. This grant was made possible by Big Nova Foundation.

Jessica Tsai

This Project By The Numbers

  • Years Active
    3
  • Amount Awarded
    $100,000
  • Institution
    Children’s Hospital Los Angeles

Additional CKc Funded Research